

Methodology

Open Access

Transformation of the rodent malaria parasite *Plasmodium chabaudi* and generation of a stable fluorescent line PcGFP_{CON}

Sarah E Reece*^{†1,2} and Joanne Thompson*^{†1}

Address: ¹Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, UK and ²Institute of Evolutionary Biology, School of Biological Sciences, University of Edinburgh, UK

Email: Sarah E Reece* - sarah.reece@ed.ac.uk; Joanne Thompson* - Joanne.Thompson@ed.ac.uk

* Corresponding authors †Equal contributors

Published: 22 September 2008

Received: 28 May 2008

Malaria Journal 2008, **7**:183 doi:10.1186/1475-2875-7-183

Accepted: 22 September 2008

This article is available from: <http://www.malariajournal.com/content/7/1/183>

© 2008 Reece and Thompson; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The rodent malaria parasite *Plasmodium chabaudi* has proven of great value in the analysis of fundamental aspects of host-parasite-vector interactions implicated in disease pathology and parasite evolutionary ecology. However, the lack of gene modification technologies for this model has precluded more direct functional studies.

Methods: The development of *in vitro* culture methods to yield *P. chabaudi* schizonts for transfection and conditions for genetic modification of this rodent malaria model are reported.

Results: Independent *P. chabaudi* gene-integrant lines that constitutively express high levels of green fluorescent protein throughout their life cycle have been generated.

Conclusion: Genetic modification of *P. chabaudi* is now possible. The production of genetically distinct reference lines offers substantial advances to our understanding of malaria parasite biology, especially interactions with the immune system during chronic infection.

Background

The development of transfection technologies in *Plasmodium* have led to substantial advances in malaria research [1-3]. The first successful transient transfection to be reported was performed in *Plasmodium gallinaceum*, followed by *Plasmodium falciparum* [4,5]. However, stable gene disruption and replacement technologies were developed first for the rodent malaria parasite, *Plasmodium berghei* [3,6-9], and have subsequently proved particularly useful in analysis of proteins mediating sexual development and transmission of the parasite through the mosquito vector [10-13]. Stable transformation has also been achieved for *Plasmodium yoelii* [14] but *P. berghei* has been the focus for the development of technical advances in transfection [2].

However, *P. berghei* causes a rapid and virulent infection leading to widespread tissue pathology and early death without effective host immune control making the investigation of host adaptive immune responses and chronic malaria infections challenging [15,16]. The lack of genetically distinct *P. berghei* clones limits its use as a model for investigations of the evolution and ecology of host-parasite interactions [17,18]. Furthermore, transmission of *P. berghei* through the mosquito vector occurs at lower temperatures (18–21 °C) and is longer (21 days) than transmission of human or other rodent malaria parasites (> 24 °C for 10–14 days) and *P. falciparum*. This may influence studies of parasite biology and development in the vector as parasite-vector interactions are sensitive to temperature (e.g. [19]).

In contrast, the rodent malaria parasite *P. chabaudi* could provide a more relevant model for investigating anti-malarial host immune responses because infections are usually controlled by host immunity (reviewed in [16,20,21]). *Plasmodium chabaudi* also shares a number of life history features with the most severe human malaria parasite, *P. falciparum*, including mature erythrocyte preference, synchronous schizogony, sequestration, rosetting, antigenic variation, and acute parasitaemia which becomes chronic [22-26]. Also, as in *P. falciparum* infections, the inability to control the consequences of the first peak of parasitaemia is a major determinant of severe disease and death. In *P. chabaudi* and *P. falciparum* most investment into sexual stages occurs after the initial peaks of parasitaemia and commitment to gametocytes appears to follow changes in anaemia and red cell dynamics [27-30]. In addition, the bank of genetically distinct and phenotypically well-characterized clones available for *P. chabaudi* is substantially larger than for all other rodent malaria models [17].

The development of gene transformation technologies for *P. chabaudi* will, therefore, provide opportunities for experimental and analytical advances in fields as diverse as immunology and evolutionary ecology. This paper presents the first report of the generation of fluorescent *P. chabaudi* lines that constitutively express high levels of Green Fluorescent Protein (GFP) throughout their life-cycle.

Methods

Preparation of parasites for transfection

To obtain parasites for transfection, male MF1 mice (10 weeks) were infected *i.p.* with 1×10^7 *P. chabaudi* parasites from clone AJ4916. 500 μ l of blood containing ring and early trophozoite-stage parasites were collected by cardiac puncture at 3 days post infection (5–10% parasitaemia). Parasites were cultured for 17–18 hours at a 1.5% dilution in complete culture medium (RPMI medium (with NaHCO₃, Hepes and L-glutamine, Invitrogen) containing 25% heat inactivated foetal calf serum (Gibco), at pH 7.25) in the presence of 10% O₂, 5% CO₂, 85% N₂, at 32°C in upright 200 ml flasks (Ikawa) in a horizontal shaking incubator at 30 rpm. Parasitized blood forming a layer at the bottom of the flask was gently removed and centrifuged at 1500 rpm for 30 sec. 5 μ l of pelleted cells (1×10^6 schizonts) were used per transfection.

Transfection and selection of transformed parasites

Gfp was introduced into the genome of *P. chabaudi* parasites, using the PbGFP_{CON} plasmid previously described [7]. 5 μ g of plasmid DNA, linearized at the Apa1 site, in 5 μ l of dH₂O was added to 100 μ l of Amaxa nucleofector™ test solution 88A6 (Basic Parasite Nucleofector™ solution 2) in the manufacturers' cuvette (Amaxa Biosystems). 5 μ l

of schizont mix was added and electroporation was carried out in an Amaxa nucleofector™ using program U33. After electroporation, 50 μ l of pre-warmed complete culture media was added and the transfection mix was immediately injected *i.v.* into an MF1 mouse. Recipient mice received 35 μ g/ml pyrimethamine in their drinking water (pH 3.5–5) for seven days post infection; the minimum pyrimethamine dose required to clear *P. chabaudi* infections of clone AJ in 24 hours (J. Thompson, personal observation). Giemsa-stained smears were scanned every one to two days and parasites that produced patent infections (days 14–20) were immediately passaged to further mice for the production of stabilate stocks.

Analysis of transformed parasites

For genetic analysis of the integration locus, DNA was isolated as previously described [2] and Southern blot and PCR analyses were performed. PCR amplifications were carried out using Qiagen Taq DNA polymerase in the presence of 'Q solution' under the following conditions; 35 cycles; anneal, 54°C, 1 min; extend, 68°C, 3 min, denature, 94°C, 10 sec. To demonstrate integration into a *ssu-rrna* locus at the 5' region, amplification was carried out with primer Pc5'F (TTGTAAGAACGCTGCTTGCTG) that is specific for *P. chabaudi ssu-rrna* sequence on *P. chabaudi* genome contig827, in the target region, and primer P15'R (TTCCCAGTCACGACGTTG) that anneals to *P. berghei d-ssu rrna* sequence in the PbGFP_{CON} plasmid. To demonstrate integration into the contig827 *ssu-rrna* locus at the 3' region, amplification was carried out with primer Pc3'R (AGAGCCCAGCGATGAC) that is specific for *P. chabaudi* contig827 *ssu-rrna* sequence in the integration site, and primer P13'F (CAATGATTCATAAATAGTTGGAC) that anneals to *P. berghei d-ssu rrna* sequence in the PbGFP_{CON} plasmid. To demonstrate the presence of *tg-dhfr* sequence, amplification was carried out with primers L190 (CGGGATCCATGCATAAACC GGTTGTGTC) + L191; CGGGATCCAAGCTTCTGTATTTCCG. To amplify circular PbGFP_{CON} plasmid, amplification was carried out with primers P1F2 (AATCATGACTTCTGTCACTGC) and P15'R. Primers Pc5'R and Pc3'R anneal specifically to sequences within *P. chabaudi* contig827 *ssu-rrna* and not to sequences within the Pb_{CON} vector. Probe template for the detection of *tg-dhfr* by Southern blots was amplified using primers L190/L191. DNA was digested with HindIII and NheI, transferred to Hybond N⁺ membrane (Amersham) and hybridized according to the manufacturers methods. Wet preparations of live parasites expressing GFP were visualized using Openlab digital imaging (Improvision). The development and progression of parasitaemia in transformed parasites was compared to the wild type ancestor by following six mice infected with 10⁶ parasitized red blood cells for each line. Infections were monitored daily to collect red blood cell density and parasitaemia data until day 14 post infection, when the acute phase parasites

had been cleared. The infection dynamics of the two lines were analysed using linear mixed-effects models, which account for repeated measures across infections. One mouse from each line was euthanized (day 10 and 11) so these infections did not contribute data for the whole time course.

Results and discussion

The optimal stage for DNA uptake by *Plasmodium* is thought to be the free merozoites, released at schizogony, that are not surrounded by red blood cell cytoplasm and membranes. *P. berghei* may, therefore, be relatively amenable to genetic transformation because schizonts developing in reticulocytes do not rupture in *in vitro* culture conditions, so high numbers can be purified. These rupture, releasing merozoites, during electroporation. In contrast, *P. chabaudi* schizonts, developing in mature red blood cells, do not arrest in culture and cannot be purified in such large numbers. For this reason, the transformation efficiency of *P. chabaudi* is likely to be considerably lower than that of *P. berghei*. The major improvements in rodent

malaria parasite transformation efficiency obtained with the Amaxa Nucleofector™ technology [9], however, together with the development of culture conditions that generate mature *P. chabaudi* schizonts suggested to us that transformation of *P. chabaudi* may now be possible.

To obtain appropriate numbers of *P. chabaudi* schizonts, the *in vitro* culture protocol described by Mackinnon *et al* [24] was adapted and scaled-up. Under these conditions, synchronous *P. chabaudi* ring-stage parasites/young trophozoites develop over 17–18 hours into a population of parasites that contain > 10% mature schizonts (Figure 1A). Schizonts produced by *in vitro* culture of *P. chabaudi* AJ blood stage parasites were transfected with the PbGFP_{CON} plasmid [7] that contains an incomplete copy of the *P. berghei d-sru-rrna* as a target region for integration, and the pyrimethamine-resistant *tgdhfr-ts* selectable cassette (*pyrR2*) for selection of transgenic parasites (Figure 2). Blast analysis of the *P. chabaudi* genome http://www.sanger.ac.uk/cgi-bin/blast/submitblast/p_chabaudi showed that there is highest identity (94%) between the




Figure 1
(A) Cultured *P. chabaudi* schizonts used for transfection (giemsa stain) (B-F) Fluorescent and bright field images of *P. chabaudi* PcGFP_{CON} blood-stage parasites. (B) two trophozoites in a rosetting red blood cell; (C) young trophozoite; (D) gametocyte; (E) schizont; (F) rupturing schizont; multiple infection of young and mature trophozoites (G); multiple infection of rings and young trophozoite (H); wild-type AJ *P. chabaudi* (I). Scale bar = 5 μ m.




Figure 2
Integration of Pb_{CON} into *P. chabaudi* *ssu-rrna*. Schematic representation of *P. chabaudi* *ssu-rrna* locus on contig827 (A). Schematic representation of linearized plasmid Pb_{CON} containing the Tgdhfr-ts cassette, conferring pyrimethamine resistance and *gfp*, flanked by *P. berghei* *d-ssu-rrna* target sequences for integration (B). Schematic representation of the contig827 *ssu-rrna* locus in PcGFP_{CON} clone 2.3, following integration of the Pb_{CON} plasmid (C). D: *tgdhfr* is present in PcGFP_{CON} (lane 1) but not wt (lane 2) DNA; amplification with L190/L191. Circular PbGFP_{CON} plasmid is absent in PcGFP_{CON} (lane 3); circular PbGFP_{CON} (lane 4); amplification with PIF2/PI5'R. Verification of the 5' integration site; Pc5'F/PI5'R amplify a product in PcGFP_{CON} (lane 5) but not in wt (lane 6) DNA. Verification of the 3' integration site; PI3'F/Pc3'R amplify a product in PcGFP_{CON} (lane 7) but not wt (lane 8) DNA. E: *Tgdhfr* is present in the genome of PcGFP_{CON} but not wt parasites. wt (lanes 1 and 2) and PcGFP_{CON} (lanes 3 and 4) genomic DNA digested with NheI (lanes 1 and 3) or HindIII (lanes 2 and 4). Integration of PcGFP into the *P. chabaudi* *ssu-rrna* locus on contig827 results in restriction enzyme digestion products of 9.4 and 15.4 kb following NheI and HindIII digestion respectively. N, NheI; H, HindIII.

P. berghei *d-ssu-rrna* target region and *P. chabaudi* *ssu-rrna* sequences on genome contig827, indicating that these are orthologous loci. Linearized PbGFP_{CON} DNA was introduced into the parasite genome by electroporation and recombinant parasites that express *tghfr* were selected by treatment with pyrimethamine.

Integration of the PbGFP_{CON} cassette into the *P. chabaudi* genome was confirmed by PCR analysis in four independ-

ent lines and line '2.3' was selected for further genetic and phenotypic analysis. In *P. chabaudi* line 2.3, PbGFP_{CON} integrated into the genome of contig 827 rRNA subunit, orthologous to the *P. berghei* *c* or *d-ssu-rrna* that have previously been shown to be non-essential genes in rodent malaria parasites [7]. Recombinant parasites develop to blood-stages with no apparent defects (Figure 1B-E) and form gametocytes that exflagellate and can infect mosquitoes.




Figure 3

Blood stage dynamics of wild type and $PcGFP_{CON}$ parasites. Average (\pm standard error) parasitaemia of six infections with $PcGFP_{CON}$ (2.3) and wild type AJ (AJ4916) parasites. Infections were initiated with 10^6 parasitized red blood cells and followed by microscopy throughout the acute phase.

The *in vivo* asexual dynamics of line 2.3 was not significantly different to wild type *P. chabaudi* AJ4916 ancestral parasites that had undergone comparable numbers of passages (Figure 3). Infections initiated with line 2.3 and AJ4916 parasites both reached patency by microscopy on day 3 post infection, peaked on day 7–8 and the acute phase lasted for 14 days. More detailed analysis of parasitaemia revealed that the lines did not differ significantly in their average parasitaemia ($F_{(1,10)} = 0.02$; $P = 0.901$). The patterns observed throughout infections were similar, though parasitaemia of line AJ4916 was significantly lower on days 8 and 9 post infection ($F_{(10,91)} = 4.96$; $P < 0.0001$). The lines did not differ in the patterns or the average levels of anaemia they caused ($F_{(1,10)} = 0.001$; $P = 0.975$). Although reversion to the wild-type genotype was observed at a low rate after multiple blood-stage passages, all $Pc-GFP_{CON}$ (line 2.3) parasites observed at day 8 of infection were GFP-positive.

Conclusion

Plasmodium chabaudi is reproducibly accessible for genetic transformation at an efficiency that is sufficient for genomic integration of introduced genes. The development of technologies that allow disruption or modification of gene expression in *P. chabaudi*, thus, opens the way for direct functional analysis of parasite proteins throughout both acute and chronic stages of an *in vivo* malaria infection, including those that have been implicated in modulation of the host immune response [31]. The gen-

eration of stable fluorescent *P. chabaudi* parasite lines also offers the opportunity for imaging of direct interactions between the parasite and host cells within a variety of host tissues.

Abbreviations

GFP: green fluorescent protein; Tgdhfr: Toxoplasma gondii Dihydrofolate reductase.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Both authors conceived and designed the project and prepared the manuscript. SR prepared and characterized parasites and JT undertook the transfection and molecular analyses. All authors read and approved the final manuscript.

Acknowledgements

We thank Blandine Franke-Fayard, Chris Janse, Margaret Mackinnon and Andy Waters for constructs and helpful discussion, and Sittiporn Pattaradilokrat, Ronnie Mooney, Sally Moore and Will Chadwick for assistance. Sequence data were produced by the *P. chabaudi* Sequencing Group at the Sanger Institute and can be obtained from http://www.sanger.ac.uk/cgi-bin/blast/submitblast/p_chabaudi. This work was funded by the MRC, BBSRC and Wellcome Trust.

References

1. Carvalho TG, Menard R: **Manipulating the Plasmodium genome.** *Curr Issues Mol Biol* 2005, **7**:39-55.

2. de Koning-Ward TF, Janse CJ, Waters AP: **The development of genetic tools for dissecting the biology of malaria parasites.** *Annu Rev Microbiol* 2000, **54**:157-185.
3. Vandijk MR, Waters AP, Janse CJ: **Stable transfection of malaria parasite blood stages.** *Science* 1995, **268**:1358-1362.
4. Goonewardene R, Daily J, Kaslow D, Sullivan TJ, Duffy P, Carter R, Mendis K, Wirth D: **Transfection of the malaria parasite and expression of firefly luciferase.** *Proc Natl Acad Sci USA* 1993, **90**:5234-5236.
5. Wu YM, Sifri CD, Lei HH, Su XZ, Wellem TE: **Transfection of *Plasmodium falciparum* within human red blood cells.** *Proc Natl Acad Sci USA* 1995, **92**:973-977.
6. de Koning-Ward TF, Thomas AWW, Waters AP, Janse CJ: **Stable expression of green fluorescent protein in blood and mosquito stages of *Plasmodium berghei*.** *Mol Biochem Parasitol* 1998, **97**:247-252.
7. Franke-Fayard B, Trueman H, Ramesar J, Mendoza J, Keur M van der, Linden R van der, Sinden RE, Waters AP, Janse CJ: **A *Plasmodium berghei* reference line that constitutively expresses GFP at a high level throughout the complete life cycle.** *Mol Biochem Parasitol* 2004, **137**(1):23-33.
8. Janse CJ, Franke-Fayard B, Mair GR, Ramesar J, Thiel C, Engelmann S, Matuschewski K, van Gemert GJ, Sauerwein RW, Waters AP: **High efficiency transfection of *Plasmodium berghei* facilitates novel selection procedures.** *Mol Biochem Parasitol* 2006, **145**:60-70.
9. Janse CJ, Franke-Fayard B, Waters AP: **Selection by flow-sorting of genetically transformed, GFP-expressing blood stages of the rodent malaria parasite, *Plasmodium berghei*.** *Nat Protoc* 2006, **1**:614-623.
10. Menard R, Sultan AA, Cortes C, Altszuler R, vanDijk MR, Janse CJ, Waters AP, Nussenzweig RS, Nussenzweig V: **Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes.** *Nature* 1997, **385**:336-340.
11. Sultan AA, Thathy V, de Koning-Ward TF, Nussenzweig V: **Complementation of *Plasmodium berghei* TRAP knockout parasites using human dihydrofolate reductase gene as a selectable marker.** *Mol Biochem Parasitol* 2001, **113**:151-156.
12. van Dijk MR, Douradinha B, Franke-Fayard B, Heussler V, van Dooren MW, van Schaijk B, van Gemert GJ, Sauerwein RW, Mota MM, Waters AP, Janse CJ: **Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells.** *Proc Natl Acad Sci USA* 2005, **102**:12194-12199.
13. van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JAM, Dode-mont HJ, Stunnenberg HG, van Gemert GJ, Sauerwein RW, Eling W: **A central role for P48/45 in malaria parasite male gamete fertility.** *Cell* 2001, **104**:153-164.
14. Mota MM, Thathy V, Nussenzweig RS, Nussenzweig V: **Gene targeting in the rodent malaria parasite *Plasmodium yoelii*.** *Mol Biochem Parasitol* 2001, **113**:271-278.
15. Augustijn KD, Kleemann R, Thompson J, Kooistra T, Crawford CE, Reece SE, Pain A, Siebum AHG, Janse CJ, Waters AP: **Functional characterization of the *Plasmodium falciparum* and *P. berghei* homologues of macrophage migration inhibitory factor.** *Infect Immun* 2007, **75**:1116-1128.
16. Langhorne J, Quin SJ, Sanni LA: **Mouse models of blood-stage malaria infections: Immune responses and cytokines involved in protection and pathology.** *Chem Immunol* 2nd edition. 2002, **80**:204-228.
17. Mackinnon MJ, Read AF: **Genetic relationships between parasite virulence and transmission in the rodent malaria *Plasmodium chabaudi*.** *Evolution* 1999, **53**:689-703 [<http://www.jstor.org/stable/2640710>].
18. Reece SE, Drew DR, Gardner A: **Sex ratio adjustment and kin discrimination in malaria parasites.** *Nature* 2008, **453**:609-614.
19. Noden B, Kent M, Beier J: **The impact of variations in temperature on early *Plasmodium falciparum* development in *Anopheles stephensi*.** *Parasitology* 1995, **111**:539-545.
20. Langhorne J, Albano FR, Hensmann M, Sanni L, Cadman E, Voisine C, Sponaas AM: **Dendritic cells, pro-inflammatory responses, and antigen presentation in a rodent malaria infection.** *Immunol Rev* 2004, **201**:35-47.
21. Stevenson MM, Urban BC: **Antigen presentation and dendritic cell biology in malaria.** *Parasite Immunol* 2006, **28**:5-14.
22. Fischer K, Chavchich M, Huestis R, Wilson DW, Kemp DJ, Saul A: **Ten families of variant genes encoded in subtelomeric regions of multiple chromosomes of *Plasmodium chabaudi*, a malaria species that undergoes antigenic variation in the laboratory mouse.** *Mol Microbiol* 2003, **48**:1209-1223.
23. Gilks CF, Walliker D, Newbold CI: **Relationships between sequestration, antigenic variation and chronic parasitism in *Plasmodium chabaudi chabaudi* – a rodent malaria model.** *Parasite Immunol* 1990, **12**:45-64.
24. Mackinnon MJ, Walker PR, Rowe JA: ***Plasmodium chabaudi*: rosetting in a rodent malaria model.** *Exp Parasitol* 2002, **101**:121-128.
25. McLean SA, Pearson CD, Phillips RS: ***Plasmodium chabaudi* – antigenic variation during recrudescence parasitemias in mice.** *Exp Parasitol* 1982, **54**:296-302.
26. Mota MM, Jarra W, Hirst E, Patnaik PK, Holder AA: ***Plasmodium chabaudi*-infected erythrocytes adhere to CD36 and bind to microvascular endothelial cells in an organ-specific way.** *Infect Immun* 2000, **68**:4135-4144.
27. Reece SE, Duncan AB, West SA, Read AF: **Host cell preference and variable transmission strategies in malaria parasites.** *Proc Biol Sci* 2005, **272**(1562):511-517.
28. Gautret P, Miltgen F, Chabaud AG, Landau I: **The production of gametocytes by rodent *Plasmodium* species in mice during phenylhydrazine induced reticulocytosis.** *Acta Parasitologica* 1997, **42**:65-7 [<http://psjc.icm.edu.pl/psjc/cgi-bin/getdoc.cgi?B97-6-22>].
29. Gautret P, Miltgen F, Gantier JC, Chabaud AG, Landau I: **Enhanced gametocyte formation by *Plasmodium chabaudi* in immature erythrocytes: Pattern of production, sequestration, and infectivity to mosquitoes.** *J Parasitol* 1996, **82**:900-906.
30. Paul REL, Ariey F, Robert V: **The evolutionary ecology of *Plasmodium*.** *Ecology Letters* 2003, **6**:866-880.
31. Thompson J, Millington OR, Garside P, Brewer JM: **What can transgenic parasites tell us about the development of *Plasmodium*-specific immune responses?** *Parasite Immunol* 2008, **30**:223-233.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

